EOFLOW v INSULET (CFI, 24 September 2024)
| Date | 24 September 2024 |
|---|---|
| Court | CFI |
| Division | Milan (IT) Central Division- Section |
| Type of action | Application Rop 333 |
| Registry reference | App_50666/2024 · ORD_51234/2024 |
| Parties | EOFLOW Co., Ltd. |
Official decision (PDF) · UPC registry entry
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
By an order of 24 September 2024 (UPC_CFI_380/2024), the panel of the Milan Central Division (A. Postiglione, presiding judge and judge-rapporteur, A.-L. Klein, U. Schwengelbeck), seised by EOFLOW Co., Ltd. under Rule 333, approved the judge-rapporteur’s order of 4 September 2024 (App_48857/2024) refusing to join INSULET Corporation’s application for provisional measures based on EP 4 201 327 with the parallel case brought before the Milan Local Division against the Italian distributor MENARINI. Leave to appeal was granted. The order sets the framework for joinder under Article 33 UPCA and Rule 340.
Question
Outside the cases of mandatory consolidation under Article 33 UPCA, is a party entitled to have provisional measures proceedings joined with a parallel case, and may the judge-rapporteur decide alone?
Decision
Outside Article 33(2) and (4), joinder is a discretionary case management measure, to be exercised proportionately. No party has a right to it (paragraphs 14 to 16 and 23). The risk of divergent decisions is minimal, since the same two judges sit on both panels, and provisional measures orders have no res judicata effect and may be revoked (paragraphs 17 to 22). Findings on validity remain provisional (paragraphs 24 to 27). Holding the hearings in parallel met EOFLOW’s concerns (paragraph 28). As to Rule 340, an order granting joinder is for the panel, as it affects the other proceedings. A refusal, which requires only consultation, may be made by the judge-rapporteur (Rule 1.2) (paragraphs 29 to 42).
Key points for practice
- Practical point: a party seeking joinder under Rule 340 must show a concrete benefit for the administration of justice, a refusal may come from the judge-rapporteur alone.
Provisions applied
- Agreement on a Unified Patent Court
- Art. 33(1)(b), (2) and (4) and Art. 73(2)(b)
- Rules of Procedure
- Rules 1.2, 198.1, 211.2, 211.3, 213, 220.2, 224.1, 302, 333, 340, 361 and 362
- Case law cited
- Court of Appeal, 5 September 2024, UPC_CoA_106/2024
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Going further
Lexicon: Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.
Dhenne Avocats blog: Pharmaceutical patents and the UPC: is the Court hostile to them?.
Publications by Matthieu Dhenne: The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Proceedings
Parties
- claimantEOFLOW Co., Ltd.22 decisions in the corpusFollow this party
Decisions in the same proceedings and documented appeals
What the record states
- Nature of the act
- Application Rop 333
- Outcome (Dhenne Avocats summary)
- Hors des cas de l'article 33 de l'Accord, la jonction est discrétionnaire et aucune partie n'y a droit. Le refus de jonction du juge rapporteur est approuvé, et l'appel est autorisé.
- Appeal
- No appeal documented in the corpus, this does not mean that no appeal was lodged.
- Instance
- First-instance decision, whether it has become final is not recorded.
Patents mentioned
EP 4 201 327mentioned in: Dhenne Avocats analysis Follow this patent
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 4 201 327Fluid delivery device with transcutaneous access tool, insertion mechanism and blood glucose monitoring for use therewith recorded proprietor: Insulet Corp | Mentioned in the analysis (role not qualified) Also mentioned in 25 other decision(s): EOFLOW v Insulet (CFI, 22 July 2025) · EOFLOW v Insulet (CoA, 18 March 2026) · EOFlow v Insulet (CoA, 26 February 2026) · EOFlow v Insulet (CoA, 4 February 2026) · EOFlow v Insulet (CoA, 29 January 2026) · Herbert Smith Freehills Kramer (applicant) in Insulet v EOFLow (CoA, 2 · Insulet v EOFLOW (CFI, 15 October 2025) · EOFLOW v Insulet (CFI, ORD_26828/2025, 5 June 2025) | not recorded | not recorded | not recorded | Espacenet · European Patent Register existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically) mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.